WINNIPEG, MANITOBA–(Marketwired – April 26, 2016) – Kane Biotech Inc. (TSX VENTURE:KNE) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that it has received a breakthrough order of its bluestem™ brand of oral care products from a major North American pet specialty store chain. The chain is one of the largest and fastest growing pet retailers in North America dedicated to providing families with food and supplies for their pets.
Kane’s bluestem products have been selling very well in select franchisee locations of the pet store chain in Canada over the past year. Starting in May 2016, its corporate locations will begin offering the bluestem brand of companion pet oral care products. The chain includes a family of stores with more than 700 locations in communities across Canada, as well as the Northeast and Midwest United States.
“We are excited to be working with the largest pet store chain in Canada and a significant player in the United States” said Mark Ahrens-Townsend, President and CEO of Kane Biotech. “Dental hygiene is being recognized more and more by dog and cat owners, as well as the pet stores who serve them, as an important part of maintaining their pets’ health. Kane’s bluestem brand, with its patent pending coactiv+™ technology, is well positioned as the premium oral care brand for quality, safety and efficacy in the marketplace today. We are very happy to align ourselves with major players in the industry who demonstrate daily a strong commitment to quality products and customer service”.
Oral health is one of the top three concerns of companion animal owners according to the American Veterinary Medical Association. bluestem™ is a premium brand of oral care products that freshens breath, helps fight plaque and tartar and improves oral hygiene for dogs and cats. Kane Biotech has conducted third party clinical studies that prove bluestem products are safe and effective for everyday use.
For specific retail locations carrying bluestem™, please visit the store locator on http://www.bluestempets.com
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, biocides, disinfectants, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
Kane Biotech uses a patent protected technology based on molecular mechanisms of biofilm formation and methods for finding compounds that inhibit or disrupt biofilms. The Corporation has evidence that this technology has potential to significantly improve the ability to prevent and/or destroy biofilms in several medical and industrial applications.
For more information, please contact:
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: the Corporation’s early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in the Corporation’s filings with Canadian securities regulatory authorities, as well as the Corporation’s ability to anticipate and manage the risks associated with the foregoing. The Corporation cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on the Corporation’s forward-looking statements to make decisions with respect to the Corporation’s, investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Corporation cannot provide assurance that actual results will be consistent with these forward-looking statements. The Corporation undertakes no obligation to update or revise any forward-looking statement.
StrixNB™, DispersinB®, Aledex®, bluestem™ and coactiv+™ are registered trademarks of Kane Biotech Inc. All Rights Reserved 2016.